At a Glance
Vela Diagnostics facts and figures
- Established in 2011
- Approximately 200 employees worldwide
- Pioneer in offering both real-time PCR and Next-Generation Sequencing on an integrated platform.
- More than 30 research or IVD tests in nine disease areas*
- 15 validated sample types
- ISO 13485:2003 certified R&D and manufacturing facilities located in Singapore, with additional R&D facilities in United States
- CLIA-certified laboratory in United States
- Global network with direct operations and distributors across North America, Europe and Asia Pacific
*regulatory status of products is based on regional availability
Select achievements and milestones
2011
- Founding of global head office in Singapore, with regional operations set up in New Jersey, US and Hamburg, Germany
- Distribution agreement with Qiagen and OEM agreement with Eppendorf
- qPCR license with Roche
- OEM agreement with Macherey Nagel
2012
- Start of direct sales in several European markets including Italy, France, UK, Benelux and Scandinavia
- Establishment of qPCR workflows and first CE-IVD tests
- OEM agreement with Life Technologies for NGS solutions
- CLIA lab license in US
- OEM agreement with Swift Biosciences
2013
- Start of direct sales in Australia and Malaysia
- Distribution agreement with AmeriLab for China and Diagnostica Longwood for Spain
2014
- Start of direct sales in Thailand
- NGS license agreement with Appistry
- Launch of the first NGS-based oncology panel for IVD use in Europe and parts of Asia
- Distribution agreement with SurgiTech AS for Estonia
2015
- Direct sales planned for India